IDEAS home Printed from https://ideas.repec.org/p/chy/respap/170chedp.html
   My bibliography  Save this paper

Prioritising investments in health technology assessment: can we assess the potential value for money?

Author

Listed:
  • Linda Davies
  • Mike Drummond

    (Centre for Health Economics, The University of York)

  • Panos Papanikoloau

Abstract

The objective was to develop an economic prioritisation model to assist those involved in (i) the selection and prioritisation of health technology assessment topics and (ii) commissioning of HTA projects. The model used decision analytic techniques to estimate the expected costs and benefits of the health care interventions which were the focus of the HTA question(s) considered by the NHS Health Technology Assessment Programme in England. Initial estimation of the value for money of HTA was conducted for a number of topics considered in 1997 and 1998. The main conclusion was that it is feasible to conduct ex ante assessments of the value for money of HTA for specific topics. However, a considerable amount of work is required to ensure that the methods used are valid, reliable, consistent and an efficient use of valuable research time.

Suggested Citation

  • Linda Davies & Mike Drummond & Panos Papanikoloau, 1999. "Prioritising investments in health technology assessment: can we assess the potential value for money?," Working Papers 170chedp, Centre for Health Economics, University of York.
    • Handle: RePEc:chy:respap:170chedp
    as

    Download full text from publisher

    File URL: http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20170.pdf
    File Function: First version, 1999
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
    2. Douglas Coyle, 1993. "Increasing the impact of economic evaluations on health care decision-making," Working Papers 108chedp, Centre for Health Economics, University of York.
    3. Stephen Palmer & Peter Smith, 1999. "Incorporating option values into the economic evaluation of health care technologies," Working Papers 166chedp, Centre for Health Economics, University of York.
    4. Romeo, Anthony A. & Wagner, Judith L. & Lee, Robert H., 1984. "Prospective reimbursement and the diffusion of new technologies in hospitals," Journal of Health Economics, Elsevier, vol. 3(1), pages 1-24, April.
    5. Drummond, Michael F. & Davies, Linda M. & Ferris, Frederick L., 1992. "Assessing the costs and benefits of medical research: The diabetic retinopathy study," Social Science & Medicine, Elsevier, vol. 34(9), pages 973-981, May.
    6. Karl Claxton & John Posnett, "undated". "An Economic Approach to Clinical Trial Design and Research Priority Setting," Discussion Papers 96/19, Department of Economics, University of York.
    Full references (including those not matched with items on IDEAS)

    Citations

    RePEc Biblio mentions

    As found on the RePEc Biblio, the curated bibliography for Economics:
    1. > Economic Development Technological Change, and Growth > Technological Change: Choices and Consequences > Technology Assessment > Health Technology Assessment

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Oortwijn, Wija J. & Vondeling, Hindrik & van Barneveld, Teus & van Vugt, Christel & Bouter, Lex M., 2002. "Priority setting for health technology assessment in The Netherlands: principles and practice," Health Policy, Elsevier, vol. 62(3), pages 227-242, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of 'payback' and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357.
    2. Sassi, Franco, 2003. "Setting priorities for the evaluation of health interventions: when theory does not meet practice," Health Policy, Elsevier, vol. 63(2), pages 141-154, February.
    3. Fleurence, Rachael L. & Torgerson, David J., 2004. "Setting priorities for research," Health Policy, Elsevier, vol. 69(1), pages 1-10, July.
    4. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of ‘payback’ and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357, December.
    5. Lazaros Andronis & Lucinda J. Billingham & Stirling Bryan & Nicholas D. James & Pelham M. Barton, 2016. "A Practical Application of Value of Information and Prospective Payback of Research to Prioritize Evaluative Research," Medical Decision Making, , vol. 36(3), pages 321-334, April.
    6. Karnon, Jonathan, 2002. "Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis," Health Policy, Elsevier, vol. 61(3), pages 329-347, September.
    7. Joanna Thorn & Joanna Coast & Lazaros Andronis, 2016. "Interpretation of the Expected Value of Perfect Information and Research Recommendations," Medical Decision Making, , vol. 36(3), pages 285-295, April.
    8. Peter Bacchetti & Charles E. McCulloch & Mark R. Segal, 2008. "Simple, Defensible Sample Sizes Based on Cost Efficiency," Biometrics, The International Biometric Society, vol. 64(2), pages 577-585, June.
    9. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
    10. Scherer, F.M., 2010. "Pharmaceutical Innovation," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 539-574, Elsevier.
    11. Rachael DiSantostefano & Andrea Biddle & John Lavelle, 2006. "The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia," PharmacoEconomics, Springer, vol. 24(2), pages 171-191, February.
    12. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    13. Grabowski, Henry & Vernon, John & DiMasi, Joseph, 2002. "Returns on R&D for 1990s New Drug Introductions," Working Papers 02-21, Duke University, Department of Economics.
    14. Karin Sundin & Ulla Fahlen & Monica Lundgren & Catrine Jacobsson, 2014. "Registered Nurses’ Experiences of Priorities in Surgery Care," Clinical Nursing Research, , vol. 23(2), pages 153-170, April.
    15. Cardoso de Mendonca, Mario Jorge & Sachsida, Adolfo & Loureiro, Paulo R. A., 2003. "A study on the valuing of biodiversity: the case of three endangered species in Brazil," Ecological Economics, Elsevier, vol. 46(1), pages 9-18, August.
    16. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    17. Steven Casper;Hannah Kettler, 2000. "The Road to Sustainability in the UK and German Biotechnology Industries," Monograph 000466, Office of Health Economics.
    18. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
    19. Simon Eckermann & Tim Coelli, 2008. "Including quality attributes in a model of health care efficiency: A net benefit approach," CEPA Working Papers Series WP032008, School of Economics, University of Queensland, Australia.
    20. Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.

    More about this item

    Keywords

    INAHTA; NCCHTA;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:chy:respap:170chedp. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Gill Forder (email available below). General contact details of provider: https://edirc.repec.org/data/chyoruk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.